Pharmacology News and Research

Latest Pharmacology News and Research

Dangers of over the counter 'natural' slimming products

The desire for a quick-fix for obesity fuels a lucrative market in so-called natural remedies. But a study of medical records in Hong Kong revealed 66 cases where people were suspected to have been poisoned by a "natural" slimming therapy. In eight cases the people became severely ill, and in one case the person died. The study is published today in the British Journal of Clinical Pharmacology.

14 Oct 2010

Research may pave way to cure cystic fibrosis

A University of Missouri researcher believes his latest work moves scientists closer to a cure for cystic fibrosis, one of the world's most common fatal genetic diseases.

13 Oct 2010

USPTO grants HemoShear patent for human cell-based surrogate systems

HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,811,782 entitled "Use of An In Vitro Hemodynamic Endothelial/Smooth Muscle Cell Co-Culture Model to Identify New Therapeutic Targets for Vascular Disease."

13 Oct 2010

Helix completes GLP toxicology study milestone in L-DOS47 development program

Helix BioPharma Corp. today announced that it has completed its definitive GLP, rodent and primate, repeat-dose toxicology studies with L-DOS47. These studies demonstrated a good safety profile in an expanded number of rodent and primate test animals, building upon Helix's positive findings from its preliminary non-GLP toxicology studies.

12 Oct 2010

Part of brain reorganizes to enhance visual abilities in deaf cats

Deaf or blind people often report enhanced abilities in their remaining senses, but up until now, no one has explained how and why that could be. Researchers at The University of Western Ontario, led by Stephen Lomber of The Centre for Brain and Mind have discovered there is a causal link between enhanced visual abilities and reorganization of the part of the brain that usually handles auditory input in congenitally deaf cats. The findings, published online in Nature Neuroscience, provide insight into the plasticity that may occur in the brains of deaf people.

11 Oct 2010

Two-day symposium marks an extraordinary decade for Brown Institute for Brain Science

Just as intense concentration allows a sharp mind to perform at its peak, a research institute that concentrates pre-eminent scientists from 11 academic departments can push back the frontiers of knowledge in a complex research area: the human brain.

8 Oct 2010

Researchers identify molecular mechanism that regulate metastasis of melanoma cells

The way melanoma cells use the immune system to spread and develop into lung tumors may lead to a therapy to decrease development of these tumors, according to Penn State researchers.

8 Oct 2010

Semi-synthetic opioid may improve withdrawal symptoms in infants

Thousands of infants each year have exposure to opioids before they are born. Over half of these infants are born with withdrawal symptoms severe enough to require opioid replacement treatment in the nursery. Such treatment is associated with long hospital stays which interferes with maternal/infant bonding. Now, a team of researchers at Thomas Jefferson University has tested a semi-synthetic opioid they say has the potential to improve the treatment of these newborns, which could save hundreds of millions in healthcare costs annually if future tests continue to show benefit.

7 Oct 2010

Patients with muscular dystrophy mount immune response to dystophin protein prior to gene therapy: Study

A clinical trial designed to replace the genetic defect causing the most common form of muscular dystrophy has uncovered an unexpected aspect of the disease. The trial, based on therapy designed by scientists at the University of North Carolina at Chapel Hill School of Medicine, showed that some patients mount an immune response to the dystrophin protein even before they have received the gene therapy.

7 Oct 2010

Repinotan blocks respiratory depressant effects of morphine without altering pain-relieving effects

A new drug called repinotan blocks the respiratory depressant effects of morphine-like opioid drugs—without altering their potent pain-relieving effects, according to a study in the October issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

6 Oct 2010

Researchers explore changes in brain regions to combat sleep apnea

According to the National Heart, Lung and Blood Institute, the average sleep apnea sufferer stops breathing and loses oxygen between five and 30 times a night. This lack of oxygen leads to a host of complications, including high blood pressure, vascular disease, an abnormal heart rhythm, or even a fatal cardiac event. Now, a team of University of Missouri researchers is exploring the changes in distinct brain regions that contribute to these symptoms in hopes of combating this common health issue.

5 Oct 2010

PAREXEL expands presence in Japan with new office in Nagoya

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that the Company has opened a new office in Nagoya, Japan to support a growing demand for a broad range of clinical development and regulatory consulting capabilities in the country and throughout the Asia/Pacific region.

From Parexel 5 Oct 2010

Research on spatial memories may lead to potential treatments for addiction and obesity

A researcher from the Faculty of Medicine & Dentistry at the University of Alberta has discovered a mechanism underlying some forms of obesity and addictions which could lead to a treatment for both diseases.

5 Oct 2010

Merck to appeal against jury verdict in retrial of federal FOSAMAX case

Merck & Co., Inc. today said it will appeal a decision by the U.S. District Court for the Southern District of New York that reduced the jury verdict from $8 million to $1.5 million but denied Merck's request for judgment in its favor or a new trial in the case of Boles v. Merck, a retrial of a federal FOSAMAX case.

5 Oct 2010

FDA provides Celsion guidance for Thermodox NDA to treat primary liver cancer

Celsion Corporation, a leading oncology drug development company, announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) that the requirements for non-clinical studies have been met for the New Drug Application (NDA) of ThermoDox.

4 Oct 2010

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.

4 Oct 2010

Sulindac drug derivative effective in preventing colon cancer: Research

Researchers in the Division of Cancer Prevention, Department of Medicine, at Stony Brook University have discovered that a novel derivative of sulindac, a non-steroidal anti-inflammatory drug (NSAID) known to prevent colon cancer, is more effective and safer than sulindac in preventing colon cancer in animals. The study results are reported in the October issue of the journal Gastroenterology.

3 Oct 2010

LSUHSC-S receives $3.9M NIDA grant to develop EMB-001 drug for cocaine dependence

Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for addiction and obesity, announced today that the Louisiana State University Health Sciences Center (LSUHSC-S) has received a $3.9 million dollar grant from the National Institute on Drug Abuse (NIDA). The grant will support the next stages of development for Embera's drug candidate EMB-001 to treat cocaine dependence, as well as advance EMB-001 into clinical testing.

1 Oct 2010

Study demonstrates rufinamide therapy is effective in reducing partial seizure frequency

Researchers from the Arkansas Epilepsy Program found treatment with rufinamide results in a significant reduction in seizure frequency compared with placebo, for patients with uncontrolled partial-onset seizures (POS).

1 Oct 2010

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note that its partner, sanofi-aventis, has today announced positive top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist discovered by Zealand Pharma, in combination with basal insulin.

30 Sep 2010

Pharmacology News and Research

Latest Pharmacology News and Research

Dangers of over the counter 'natural' slimming products

Research may pave way to cure cystic fibrosis

USPTO grants HemoShear patent for human cell-based surrogate systems

Helix completes GLP toxicology study milestone in L-DOS47 development program

Part of brain reorganizes to enhance visual abilities in deaf cats

Two-day symposium marks an extraordinary decade for Brown Institute for Brain Science

Researchers identify molecular mechanism that regulate metastasis of melanoma cells

Semi-synthetic opioid may improve withdrawal symptoms in infants

Patients with muscular dystrophy mount immune response to dystophin protein prior to gene therapy: Study

Repinotan blocks respiratory depressant effects of morphine without altering pain-relieving effects

Researchers explore changes in brain regions to combat sleep apnea

PAREXEL expands presence in Japan with new office in Nagoya

Research on spatial memories may lead to potential treatments for addiction and obesity

Merck to appeal against jury verdict in retrial of federal FOSAMAX case

FDA provides Celsion guidance for Thermodox NDA to treat primary liver cancer

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Sulindac drug derivative effective in preventing colon cancer: Research

LSUHSC-S receives $3.9M NIDA grant to develop EMB-001 drug for cocaine dependence

Study demonstrates rufinamide therapy is effective in reducing partial seizure frequency

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

Pittcon Highlights: Pharmaceutical & Biologic eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Pharmacology News and Research

Latest Pharmacology News and Research

Pittcon Highlights: Pharmaceutical & Biologic eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in